New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New clinical trial results show LT3001’s promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.
A recently published randomized trial (NCT03728738) of patients with large vessel occlusion (LVO) stroke revealed that a 0° head position prior to endovascular thrombectomy (EVT) was safe and the most optimal positioning to prevent clinical worsening.
James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.
The Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center highlighted the benefits and challenges of using stiripentol, an FDA-approved treatment for Dravet syndrome.
A recent study presented at AES 2024 showed that fewer than 15% of doses of diazepam nasal spray administered to pediatric patients with epilepsy required a second dose in 24 hours.
In most states in the US, there is a change in time twice a year—once in the spring, and once in the fall. The idea behind daylight saving time (DST) is to make better use of the available daylight during the longer days of the year by shifting an hour of daylight from the morning… Read More
The field of stroke has advanced its care approaches for these patients in the past couple decades. Despite the progress that has been made in this field, though, there is a big challenge that lingers for patients and is often the focus of conversations in the clinical setting: racial disparities in stroke care.
